|
WO2020243590A1
|
|
Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
|
|
WO2020198383A1
|
|
Methods of diagnosis and treatment of liver diseases using obeticholic acid
|
|
WO2020163201A1
|
|
Treatment and prevention of intestinal inflammatory diseases with a bile acid derivative
|
|
WO2020097167A1
|
|
Methods of using obeticholic acid
|
|
US2020197414A1
|
|
Treatment of fibrosis using FXR ligands
|
|
CN111050772A
|
|
Isotopically labelled bile acid derivatives
|
|
AU2018288883A1
|
|
Methods and intermediates for the preparation of bile acid derivatives
|
|
WO2018226724A1
|
|
Treatment and prevention of diabetic eye diseases with a bile acid derivatives
|
|
WO2018222701A1
|
|
Treatment of renal diseases with a bile acid derivative
|
|
CN110831602A
|
|
Crystalline forms of obeticholic acid
|
|
CA3053935A1
|
|
Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof
|
|
AU2017336803A1
|
|
Crystalline forms of a bile acid derivative
|
|
US2018256600A1
|
|
Methods of treating cancer
|
|
TW201832768A
|
|
Methods Of Treating Cancer
|
|
TW201738254A
|
|
Methods for the preparation of obeticholic acid and derivatives thereof
|
|
AU2017249226A1
|
|
Methods of treating cancer
|
|
EP3426348A1
|
|
3-desoxy derivative and pharmaceutical compositions thereof
|
|
CN108348533A
|
|
The method for preparing shellfish cholic acid and its derivative difficult to understand
|
|
AU2016335765A1
|
|
Farnesoid X receptor modulators
|
|
MX2018003649A
|
|
Methods and intermediates for the preparation bile acid derivatives.
|
